Like I said....This stock will start its reversal this week. 10 days from now the volume and price will look differently than today.
This stock will start its reversal this week. 10 days from now the volume and price will look differently than today.
I own 14 Bio's and IDRA is one of them. The company has a lot to offer....from the IDRA MB....One of the biggest being that the company will be revealing the first TWO disease indications for the GSO platform in the fourth quarter. They had been expecting the first disease target to be revealed, but it now appears that Milano wants to move forward more quickly by targeting 2 diseases to start. He also stated that, while the company has made many key hires in the quarter that have had immediate impact on the company that they are not finished adding. I take that to mean that we will be seeing a new CMO coming fairly soon and they are still searching for the best candidate. I did detect a hint of optimism in a report that generally is seen as neutral with the report stating that the company is moving "rapidly" toward the release of the 8400 data. The cash burn rate is very reasonable at $25 million for the last 6 months, the majority of that in R&D, and still over $100 million in cash. This is a very different company from most other developmental biotechs, thanks to the vast pipeline they have, of which compounds in 5 different indications---JUST WITH THE TLR's---will either be in trials or have results in within the next 6 months---along with having a strategic research partnership with MD Anderson(apparently with another collaborative trial coming, too). And we will find out the first 2 GSO targets, rather than just one, which will also be in patient trials within the next 6 months. This is a very exciting and dynamic company that is moving forward very quickly, and the milestones that we are waiting for will begin moving by very quickly---with the biggest one so far coming in the few months-----hopefully with a BIG splash at ASH
XON does not develop or sell any pharma products that I am aware of, so there has to be another company Riley was referring to? Either way Kirk and Riley are up to something.....and it's going to be BIG and its going to take a while!
Maybe XON is the large specialty pharma that Riley mentioned in the Q1 CC. We will find out soon
XON expertise could maximize value for Trimesta/other similar products. Keep Riley focused on SYN 004, 010, Acetobacter whooping Cough and other.
GERMANTOWN, Md. and ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ -- Intrexon Corporation (XON), a leader in synthetic biology, and Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder. Through the ECC, the companies plan to utilize Intrexon's ActoBiotics™ platform providing a proprietary method of delivering therapeutic protein and peptides to the gastrointestinal (GI) tract through food-grade microbes.
HMMMMM. Good new I guess!
What a nice way to kick off my week. Sold 22k shares in pre market between $6.88. - $7.40, truly blessed. Now will all of the proceeds into OPK and CEMP
Stock halted! We will open above $4 60